A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727 | Recruiting Phase 3 DMC FDA Drug

• 3 other identifiers: CDAK539A123032025-523555-66-002025
• Study Type: interventional
• Target: 460
• Locations: 18 countries
• Sites: 109

Brief Summary

The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.

Conditions

Post-polycythemia Vera Myelofibrosis (PPV-MF); Post-essential Thrombocythemia Myelofibrosis (PET-MF); Primary Myelofibrosis (PMF)

Keywords

Pelabresib (DAK539); Ruxolitinib; Adult participants; Myelofibrosis (MF)

Outcome Measures

Primary Outcomes (4)

• Number of Participants with Splenic Response (SVR35) by Central Radiology Reads at Week 24 in participants with baseline total symptom score (TSS) ≥ 25

  Spleen Response (SVR35) is defined as achieving a reduction of at least 35 percent in spleen volume from baseline to Week 24, as measured by magnetic resonance imaging (MRI) or computed tomography (CT) scan, and assessed by a centralized radiology review in participants with baseline TSS ≥ 25.

  Week 24

• Absolute change from baseline in total symptom score (TSS) at Week 24 in participants with baseline TSS ≥ 25

  Symptom improvement at Week 24 is defined as the absolute change from baseline in the total symptom score (TSS) at Week 24, as measured by the Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0) in participants with baseline TSS ≥ 25.

  Baseline, Week 24

• Number of Participants with Splenic Response (SVR35) by Central Radiology Reads at Week 24 in participants with baseline TSS ≥ 15

  Spleen Response (SVR35) is defined as achieving a reduction of at least 35 percent in spleen volume from baseline to Week 24, as measured by magnetic resonance imaging (MRI) or computed tomography (CT) scan, and assessed by a centralized radiology review in participants with baseline TSS ≥ 15.

  Week 24

• Absolute change from baseline in total symptom score (TSS) at Week 24 in participants with baseline TSS ≥ 15

  Symptom improvement at Week 24 is defined as the absolute change from baseline in the total symptom score (TSS) at Week 24, as measured by the Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0) in participants with baseline TSS ≥ 15.

  Baseline, Week 24

Secondary Outcomes (24)

• Number of Participants with Splenic Response (SVR35) by Central Radiology Reads over time

  Week 12, Week 36, Week 48 and every 12 weeks thereafter till End of Study (an average of 3 years)

• Absolute change from baseline and percentage change from baseline in spleen volume over time

  Baseline, Week 12, Week 24, Week 36, Week 48, and every 12 weeks thereafter till End of Study (an average of 3 years)

• Time to first SVR35 response

  From date of randomization to the date of first SVR35 response, assessed up to approximately 3 years

• Duration of first SVR35 response

  From first SVR35 response to loss of response, assessed up to approximately 3 years

• Number of Participants with TSS50 response at Week 24

  Week 24

Study Arms (2)

Arm 1: Pelabresib + Ruxolitinib

EXPERIMENTAL

Participants in this arm receive pelabresib (DAK539) orally once daily for 14 days of each 21-day cycle, in combination with ruxolitinib, which is taken orally twice daily throughout each cycle. Participants may continue receiving study treatment until they experience unacceptable toxicity, disease progression, or until either the investigator or the participant decides to discontinue treatment.

Drug: Pelabresib; Drug: Ruxolitinib

Arm 2: Placebo + Ruxolitinib

PLACEBO COMPARATOR

Participants in this arm receive a matching placebo orally once daily for 14 days of each 21-day cycle, together with ruxolitinib, which is also taken orally twice daily throughout each cycle. Participants may continue receiving study treatment until they experience unacceptable toxicity, disease progression, or until either the investigator or the participant decides to discontinue treatment.

Drug: Ruxolitinib; Drug: Placebo

Interventions

Pelabresib DRUG

Pelabresib monohydrate tablets

Also known as: DAK539

Arm 1: Pelabresib + Ruxolitinib

Placebo DRUG

Matches pelabresib

Arm 2: Placebo + Ruxolitinib

Ruxolitinib DRUG

Ruxolitinib phosphate tablets

Also known as: INC424

Arm 1: Pelabresib + Ruxolitinib; Arm 2: Placebo + Ruxolitinib

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants have diagnosis of primary myelofibrosis (PMF) or post-polycythemia vera myelofibrosis (post-PV MF) or post-essential thrombocythemia myelofibrosis (post-ET MF) according to the International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemias 2022
• DIPSS risk category of intermediate-1, intermediate-2 or high-risk
• Spleen volume ≥ 450 cm3 by CT or MRI scan (local read sufficient if no central read available)
• Have an average TSS of ≥15 within 7 days prior to randomization, using MFSAF v. 4.0 (at least 4 out of 7 TSS assessments required for average calculation)
• Participants with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
• Blasts \<5% in peripheral blood. Assessment of blasts in peripheral blood is mandatory at screening
• Platelet count ≥ 100 x 10\^9/L in the absence of growth factors or transfusions for the previous 4 weeks

You may not qualify if:

• Prior splenectomy at any time or splenic irradiation in the previous 6 months
• Prior hematopoietic cell transplant or participant anticipated to receive a hematopoietic cell transplant within 24 weeks from the date of randomization
• Blasts ≥ 5% in bone marrow if results available at screening or history of accelerated phase (AP) or leukemic transformation
• History of a malignancy (other than MF, PPV-MF or PET-MF) in the past 3 years in need of systemic treatment
• Received any approved or investigational agent other than hydroxyurea or anagrelide for the treatment of MF within 14 days of first dose of study treatment or within 5 half-lives of the approved or investigational agent, whichever is longer
• Prior treatment with any JAK inhibitor or Bromodomain and extraterminal domain (BET) inhibitor

Sponsors & Collaborators

• Novartis Pharmaceuticals: lead

Study Sites (111)

Yale University School Of Medicine

New Haven, Connecticut, 06520, United States

RECRUITING

Florida Cancer Specialist South Reg

Fort Myers, Florida, 33916, United States

RECRUITING

The Anderson Family Cancer Institute

Jupiter, Florida, 33458, United States

RECRUITING

Miami NS Ins Baptist Health S FL

Miami, Florida, 33176, United States

RECRUITING

Florida Cancer Specialists-North

St. Petersburg, Florida, 33705, United States

RECRUITING

Florida Cancer Specialists East

Stuart, Florida, 34994, United States

RECRUITING

Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322, United States

RECRUITING

Franciscan Health Indianapolis

Indianapolis, Indiana, 42637, United States

RECRUITING

American Oncology Partners PA Center for Cancer and Blood Disorders

Bethesda, Maryland, 20817, United States

RECRUITING

Summit Medical Group Oncology

Berkeley Heights, New Jersey, 07922, United States

RECRUITING

New York Oncology Hematology P C

Albany, New York, 12206, United States

RECRUITING

The Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43221, United States

RECRUITING

Texas Oncology PA Dallas Presbyterian Hospital

Dallas, Texas, 75231, United States

RECRUITING

MD Anderson Cancer Center

Houston, Texas, 77030, United States

RECRUITING

SCRI Texas Oncology Northeast Texas

Tyler, Texas, 75702, United States

RECRUITING

Fred Hutch Cancer Research

Seattle, Washington, 98109, United States

RECRUITING

Novartis Investigative Site

Buenos Aires, Buenos Aires F.D., 1221, Argentina

RECRUITING

Novartis Investigative Site

CABA, C1181ACH, Argentina

RECRUITING

Novartis Investigative Site

Capital Federal, C1114AAN, Argentina

RECRUITING

Novartis Investigative Site

Córdoba, X5016KEH, Argentina

RECRUITING

Novartis Investigative Site

Adelaide, South Australia, 5000, Australia

RECRUITING

Novartis Investigative Site

Clayton, Victoria, 3168, Australia

RECRUITING

Novartis Investigative Site

Graz, 8036, Austria

RECRUITING

Novartis Investigative Site

Sankt Pölten, 3100, Austria

RECRUITING

Novartis Investigative Site

Goiânia, Goiás, 74605-050, Brazil

RECRUITING

Novartis Investigative Site

Florianópolis, Santa Catarina, 88020-210, Brazil

RECRUITING

Novartis Investigative Site

Barretos, São Paulo, 14784-400, Brazil

RECRUITING

Novartis Investigative Site

Hefei, Anhui, 230001, China

RECRUITING

Novartis Investigative Site

Guangzhou, Guangdong, 510080, China

RECRUITING

Novartis Investigative Site

Guangzhou, Guangdong, 510515, China

RECRUITING

Novartis Investigative Site

Wuhan, Hubei, 430022, China

RECRUITING

Novartis Investigative Site

Wuhan, Hubei, 430030, China

RECRUITING

Novartis Investigative Site

Nanjing, Jiangsu, 210029, China

RECRUITING

Novartis Investigative Site

Nantong, Jiangsu, 226000, China

RECRUITING

Novartis Investigative Site

Nanchang, Jiangxi, 330006, China

RECRUITING

Novartis Investigative Site

Changchun, Jilin, 130021, China

RECRUITING

Novartis Investigative Site

Jinan, Shandong, 250012, China

RECRUITING

Novartis Investigative Site

Yantai, Shandong, 264000, China

RECRUITING

Novartis Investigative Site

Kunming, Yunnan, 650101, China

RECRUITING

Novartis Investigative Site

Hangzhou, Zhejiang, 310003, China

RECRUITING

Novartis Investigative Site

Wenzhou, Zhejiang, 325000, China

RECRUITING

Novartis Investigative Site

Beijing, 100730, China

RECRUITING

Novartis Investigative Site

Chongqing, 400016, China

RECRUITING

Novartis Investigative Site

Fuzhou, 350001, China

RECRUITING

Novartis Investigative Site

Shanghai, 200025, China

RECRUITING

Novartis Investigative Site

Shenyang, 110004, China

RECRUITING

Novartis Investigative Site

Tianjin, 300020, China

RECRUITING

Novartis Investigative Site

Ostrava, Poruba, 708 52, Czechia

RECRUITING

Novartis Investigative Site

Brno, 625 00, Czechia

RECRUITING

Novartis Investigative Site

Hradec Králové, 500 05, Czechia

RECRUITING

Novartis Investigative Site

Olomouc, 779 00, Czechia

RECRUITING

Novartis Investigative Site

Brest, 29200, France

RECRUITING

Novartis Investigative Site

Nîmes, 30029, France

RECRUITING

Novartis Investigative Site

Poitiers, 86021, France

RECRUITING

Novartis Investigative Site

Mannheim, Baden-Wurttemberg, 68305, Germany

RECRUITING

Novartis Investigative Site

Aachen, 52074, Germany

RECRUITING

Novartis Investigative Site

Aurangabad, Maharashtra, 431005, India

RECRUITING

Novartis Investigative Site

Pune, Maharashtra, 411006, India

RECRUITING

Novartis Investigative Site

Rishikesh, Uttarakhand, 249203, India

RECRUITING

Novartis Investigative Site

Kolkata, West Bengal, 700014, India

RECRUITING

Novartis Investigative Site

Delhi, 110085, India

RECRUITING

Novartis Investigative Site

Meldola, FC, 47014, Italy

RECRUITING

Novartis Investigative Site

Florence, FI, 50134, Italy

RECRUITING

Novartis Investigative Site

Padova, PD, 35128, Italy

RECRUITING

Novartis Investigative Site

Roma, RM, 00161, Italy

RECRUITING

Novartis Investigative Site

Verona, VR, 37134, Italy

RECRUITING

Novartis Investigative Site

Novara, 28100, Italy

RECRUITING

Novartis Investigative Site

Kamogawa, Chiba, 2968602, Japan

RECRUITING

Novartis Investigative Site

Sapporo, Hokkaido, 0030006, Japan

RECRUITING

Novartis Investigative Site

Kobe, Hyōgo, 6500047, Japan

RECRUITING

Novartis Investigative Site

Shiwa-Gun, Iwate, 0283695, Japan

RECRUITING

Novartis Investigative Site

Tsu, Mie-ken, 5148507, Japan

RECRUITING

Novartis Investigative Site

Bunkyo Ku, Tokyo, 1138431, Japan

RECRUITING

Novartis Investigative Site

Bunkyo-ku, Tokyo, 1138603, Japan

RECRUITING

Novartis Investigative Site

Chūō, Yamanashi, 4093898, Japan

RECRUITING

Novartis Investigative Site

Fukuoka, 8128582, Japan

RECRUITING

Novartis Investigative Site

Miyazaki, 8891692, Japan

RECRUITING

Novartis Investigative Site

George Town, Pulau Pinang, 10450, Malaysia

RECRUITING

Novartis Investigative Site

Kota Kinabalu, Sabah, 88586, Malaysia

RECRUITING

Novartis Investigative Site

Kuching, Sarawak, 93586, Malaysia

RECRUITING

Novartis Investigative Site

Johor Bahru, 80100, Malaysia

RECRUITING

Novartis Investigative Site

Kuala Selangor, 68000, Malaysia

RECRUITING

Novartis Investigative Site

Katowice, 40-519, Poland

RECRUITING

Novartis Investigative Site

Lublin, 20-090, Poland

RECRUITING

Novartis Investigative Site

Skorzewo, 60-185, Poland

RECRUITING

Novartis Investigative Site

Warsaw, 02-776, Poland

RECRUITING

Novartis Investigative Site

Wałbrzych, 58-309, Poland

RECRUITING

Novartis Investigative Site

Suwon, Gyeonggi-do, 16247, South Korea

RECRUITING

Novartis Investigative Site

Jeonju, Jeollabuk-do, 54907, South Korea

RECRUITING

Novartis Investigative Site

Seoul, Yangcheon Gu, 07985, South Korea

RECRUITING

Novartis Investigative Site

Busan, 49241, South Korea

RECRUITING

Novartis Investigative Site

Seoul, 03080, South Korea

RECRUITING

Novartis Investigative Site

Seoul, 05505, South Korea

RECRUITING

Novartis Investigative Site

Seoul, 06351, South Korea

RECRUITING

Novartis Investigative Site

Seoul, 06591, South Korea

RECRUITING

Novartis Investigative Site

Barcelona, 08035, Spain

RECRUITING

Novartis Investigative Site

Las Palmas GC, 35010, Spain

RECRUITING

Novartis Investigative Site

Basel, 4058, Switzerland

RECRUITING

Novartis Investigative Site

Bern, 3010, Switzerland

RECRUITING

Novartis Investigative Site

Geneva, 1211, Switzerland

RECRUITING

Novartis Investigative Site

Genolier, 1272, Switzerland

RECRUITING

Novartis Investigative Site

Changhua, 50006, Taiwan

RECRUITING

Novartis Investigative Site

Kaohsiung City, 80756, Taiwan

RECRUITING

Novartis Investigative Site

Tainan, 704302, Taiwan

RECRUITING

Novartis Investigative Site

Taipei, 10002, Taiwan

RECRUITING

Novartis Investigative Site

Istanbul, Fatih, 34098, Turkey (Türkiye)

RECRUITING

Novartis Investigative Site

Ankara, Sihhiye Altindag, 06230, Turkey (Türkiye)

RECRUITING

Novartis Investigative Site

Ankara, 06000, Turkey (Türkiye)

RECRUITING

Novartis Investigative Site

Izmir, 35060, Turkey (Türkiye)

RECRUITING

Novartis Investigative Site

Kocaeli, 41380, Turkey (Türkiye)

RECRUITING

Novartis Investigative Site

Samsun, 55200, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Primary Myelofibrosis

Interventions

ruxolitinib

Condition Hierarchy (Ancestors)

Myeloproliferative Disorders; Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Novartis Pharmaceuticals

  Novartis Pharmaceuticals

  STUDY DIRECTOR

Central Study Contacts

Novartis Pharmaceuticals

CONTACT

1-888-669-6682; novartis.email@novartis.com

Novartis Pharmaceuticals

CONTACT

+41613241111; novartis.email@novartis.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 15, 2026
• First Posted: January 22, 2026
• Study Start: May 27, 2026
• Primary Completion (Estimated): May 17, 2028
• Study Completion (Estimated): December 27, 2030
• Last Updated: October 2, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will share

Locations

CH (4); JP (10); IT (6); US (16); KR (8); CN (20); AU (2); AR (4); IN (5); TW (4); MY (5); TU (6); PL (5); BR (3); FR (3); CZ (4); ES (2); DE (2)